Xu Ting

Xu Ting (board member) discloses dealings in 2 companies, chiefly Alphamab Oncology - B and Newmarket Corp. We count 18 filings; the first trade dates from 12 December 2019 and the latest from 4 June 2026.

On the open market, the record shows 5 purchases worth €46.0M and 4 sales worth €85.4M. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 4 share grants. 2026 to date brings 2 purchases and no sales.

Half of the purchases are above €319k and half below. Of 4 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 67% of cases; the median change was +14.2%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 23 June 2026, the filings show an open-market purchase worth €428k in Alphamab Oncology - B. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.